Login to Your Account



Neurimmune Inks $380M Deal In Alzheimer's With Biogen Idec

By Cormac Sheridan


Wednesday, November 21, 2007
Neurimmune Therapeutics AG, an early stage biotechnology firm specializing in developing antibody-based therapies for neurodegenerative conditions, entered an alliance on Alzheimer's disease with Biogen Idec worth up to $380 million in up-front and milestone payments. Neurimmune also would receive royalties on eventual product sales. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription